CGEM: Cullinan Oncology Inc. Stocks News on November 19, 2025

Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting

CGEM

GlobeNewswire

9 days ago

Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting

CGEM

Associated Press Finance

13 days ago

Cullinan Therapeutics: Q3 Earnings Snapshot

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

CGEM

GlobeNewswire

13 days ago

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

CGEM

GlobeNewswire

16 days ago

Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025

CGEM

PR Newswire

a month ago

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025

Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal

CGEM

BioPharma Dive

5 months ago

Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

CGEM

GlobeNewswire

5 months ago

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

CGEM

PR Newswire

6 months ago

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference

CGEM

GlobeNewswire

6 months ago

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

CGEM

GlobeNewswire

6 months ago

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

CGEM

GlobeNewswire

6 months ago

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States

CGEM

GlobeNewswire

7 months ago

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

CGEM

GlobeNewswire

7 months ago

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

CGEM

GlobeNewswire

7 months ago

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

CGEM

GlobeNewswire

9 months ago

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

CGEM

GlobeNewswire

9 months ago

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

CGEM

Simply Wall St.

10 months ago

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

CGEM

GlobeNewswire

10 months ago

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

CGEM

PR Newswire

10 months ago

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

CGEM

GlobeNewswire

a year ago

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

CGEM

GlobeNewswire

a year ago

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

CGEM

GlobeNewswire

a year ago

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

CGEM

GlobeNewswire

a year ago

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

CGEM

GlobeNewswire

a year ago

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

CGEM

GlobeNewswire

a year ago

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

CGEM

GlobeNewswire

a year ago

Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

CGEM

GlobeNewswire

a year ago

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

CGEM

GlobeNewswire

a year ago

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

CGEM

Simply Wall St.

a year ago

We Think Cullinan Therapeutics (NASDAQ:CGEM) Can Afford To Drive Business Growth

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

CGEM

GlobeNewswire

a year ago

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

CGEM

Simply Wall St.

a year ago

Institutional owners may ignore Cullinan Therapeutics, Inc.'s (NASDAQ:CGEM) recent US$92m market cap decline as longer-term profits stay in the green

Cullinan Therapeutics announces success for zipalertinib as combo therapy

CGEM

Clinical Trials Arena

a year ago

Cullinan Therapeutics announces success for zipalertinib as combo therapy

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

CGEM

GlobeNewswire

a year ago

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

CGEM

GlobeNewswire

a year ago

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

CGEM

GlobeNewswire

a year ago

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

CGEM

MT Newswires

2 years ago

HC Wainwright Adjusts Price Target on Cullinan Oncology to $28 From $29, Maintains Buy Rating

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

CGEM

GlobeNewswire

2 years ago

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

CGEM

GuruFocus.com

2 years ago

Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...

CGEM

MT Newswires

2 years ago

Stifel Initiates Cullinan Oncology With Buy Rating, $40 Price Target

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

CGEM

GlobeNewswire

2 years ago

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?

CGEM

Benzinga

2 years ago

Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

CGEM

GlobeNewswire

2 years ago

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity

CGEM

Benzinga

2 years ago

Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

CGEM

GlobeNewswire

2 years ago

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

CGEM

GlobeNewswire

2 years ago

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

Cullinan changes name, pivots to autoimmune disease

CGEM

BioPharma Dive

2 years ago

Cullinan changes name, pivots to autoimmune disease

CGEM

GuruFocus.com

2 years ago

Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results

CGEM

Simply Wall St.

2 years ago

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

CGEM

GlobeNewswire

2 years ago

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

$Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma$

CGEM

GlobeNewswire

2 years ago

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Cullinan Oncology to Participate in Upcoming Investor Conferences

CGEM

GlobeNewswire

2 years ago

Cullinan Oncology to Participate in Upcoming Investor Conferences

CGEM

Insider Monkey

2 years ago

13 Best Booming Stocks to Buy Right Now

Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc

CGEM

GuruFocus.com

2 years ago

Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc

Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

CGEM

GlobeNewswire

2 years ago

Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

MAG Silver (MAG) Reports Solid Production at Juanicipio

CGEM

Zacks

2 years ago

MAG Silver (MAG) Reports Solid Production at Juanicipio

Global Ship Lease (GSL) Advances While Market Declines: Some Information for Investors

CGEM

Zacks

2 years ago

Global Ship Lease (GSL) Advances While Market Declines: Some Information for Investors

CGEM

GlobeNewswire

2 years ago

Genie Energy Unveils Insurance Strategy

Paragon 28 Launches the Mister Tendon™ Harvester System – The First and Only Minimally Invasive Harvesting System for FHL and FDL Tendon Transfer Procedures

CGEM

Business Wire

2 years ago

Paragon 28 Launches the Mister Tendon™ Harvester System – The First and Only Minimally Invasive Harvesting System for FHL and FDL Tendon Transfer Procedures

CGEM

Newsfile

2 years ago

Genie Energy Announces Participation in The Microcap Conference

Obsidian Energy Announces 2024 Guidance With 12 Percent Growth in Average Annual Production to 36,000 boe/d

CGEM

Newsfile

2 years ago

Obsidian Energy Announces 2024 Guidance With 12 Percent Growth in Average Annual Production to 36,000 boe/d

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

CGEM

GlobeNewswire

2 years ago

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares

CGEM

GuruFocus.com

2 years ago

Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares

CGEM

Associated Press Finance

2 years ago

City Holding: Q4 Earnings Snapshot

City Holding Company Announces Record Annual Earnings

CGEM

Business Wire

2 years ago

City Holding Company Announces Record Annual Earnings

Solar Stocks Enphase, Sunnova Jump On Upgrade. Why Analyst Sees Upside After Rough Year.

CGEM

Investor's Business Daily

2 years ago

Solar Stocks Enphase, Sunnova Jump On Upgrade. Why Analyst Sees Upside After Rough Year.

Dow closes above 38,000, Verizon, JNJ, and PG report: Yahoo Finance Live

CGEM

Yahoo Finance Video

2 years ago

Dow closes above 38,000, Verizon, JNJ, and PG report: Yahoo Finance Live

Obsidian Energy Announces 2024 Guidance and Webcast

CGEM

Newsfile

2 years ago

Obsidian Energy Announces 2024 Guidance and Webcast

Trump-Tied SPAC Surges 175% in Six-Day Rally

CGEM

Bloomberg

2 years ago

Trump-Tied SPAC Surges 175% in Six-Day Rally

Here's Why Model N (MODN) is a Strong Growth Stock

CGEM

Zacks

2 years ago

Here's Why Model N (MODN) is a Strong Growth Stock

NGL Energy Partners LP Announces $700 Million Senior Secured Term Loan Facility and Provides Financial Update

CGEM

Business Wire

2 years ago

NGL Energy Partners LP Announces $700 Million Senior Secured Term Loan Facility and Provides Financial Update

Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence

CGEM

Business Wire

2 years ago

Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence

Paragon 28 Announces First Cases and Limited Market Release of the Bun-Yo-Matic™ – A Next Generation Clamp and Cut Guide System for Lapidus Bunion Procedures

CGEM

Business Wire

2 years ago

Paragon 28 Announces First Cases and Limited Market Release of the Bun-Yo-Matic™ – A Next Generation Clamp and Cut Guide System for Lapidus Bunion Procedures

The 3 Most Undervalued Biotech Stocks to Buy in January

CGEM

InvestorPlace

2 years ago

The 3 Most Undervalued Biotech Stocks to Buy in January

Will Weakness in Genie Energy Ltd.'s (NYSE:GNE) Stock Prove Temporary Given Strong Fundamentals?

CGEM

Simply Wall St.

2 years ago

Will Weakness in Genie Energy Ltd.'s (NYSE:GNE) Stock Prove Temporary Given Strong Fundamentals?

Better Than BTC: 7 Crypto Stocks With the Potential to Outperform Bitcoin

CGEM

InvestorPlace

2 years ago

Better Than BTC: 7 Crypto Stocks With the Potential to Outperform Bitcoin

Cipher Mining to Present at the 26th Annual Needham Growth Conference

CGEM

GlobeNewswire

2 years ago

Cipher Mining to Present at the 26th Annual Needham Growth Conference

Walker & Dunlop Investment Sales Team Grows North and South Carolina Platform With New Managing Director

CGEM

Business Wire

2 years ago

Walker & Dunlop Investment Sales Team Grows North and South Carolina Platform With New Managing Director

UMH PROPERTIES, INC. DECLARES COMMON AND PREFERRED DIVIDENDS

CGEM

GlobeNewswire

2 years ago

UMH PROPERTIES, INC. DECLARES COMMON AND PREFERRED DIVIDENDS

3D Systems Announces Executive Leadership Changes

CGEM

GlobeNewswire

2 years ago

3D Systems Announces Executive Leadership Changes

3 No-Brainer Stocks to Buy With $20 Right Now

CGEM

Motley Fool

2 years ago

3 No-Brainer Stocks to Buy With $20 Right Now

Unpacking Q3 Earnings: PubMatic (NASDAQ:PUBM) In The Context Of Other Advertising Software Stocks

CGEM

StockStory

2 years ago

Unpacking Q3 Earnings: PubMatic (NASDAQ:PUBM) In The Context Of Other Advertising Software Stocks

ArcelorMittal (MT) Rejects Italy Government's Stake Plan in ADI

CGEM

Zacks

2 years ago

ArcelorMittal (MT) Rejects Italy Government's Stake Plan in ADI

Vimeo, Inc.'s (NASDAQ:VMEO) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

CGEM

Simply Wall St.

2 years ago

Vimeo, Inc.'s (NASDAQ:VMEO) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

3D Systems to Attend 26th Annual Needham Growth Conference

CGEM

GlobeNewswire

2 years ago

3D Systems to Attend 26th Annual Needham Growth Conference

IHOP® Kicks off 2024 With a Rooty Tooty Fresh ‘N Fruity® Extravaganza

CGEM

Business Wire

2 years ago

IHOP® Kicks off 2024 With a Rooty Tooty Fresh ‘N Fruity® Extravaganza

Primerica Senior Field Leaders Meet to Plan for Growth in 2024 and Beyond

CGEM

Business Wire

2 years ago

Primerica Senior Field Leaders Meet to Plan for Growth in 2024 and Beyond

United Natural Foods Releases Updated Selling Show 2024 Schedule

CGEM

Business Wire

2 years ago

United Natural Foods Releases Updated Selling Show 2024 Schedule

Canaan Secures Follow-On Purchase Orders from Cipher and Stronghold

CGEM

PR Newswire

2 years ago

Canaan Secures Follow-On Purchase Orders from Cipher and Stronghold

Diversified Closes Value Enhancing Asset Sale

CGEM

ACCESSWIRE

2 years ago

Diversified Closes Value Enhancing Asset Sale

Fast-paced Momentum Stock Triumph Group (TGI) Is Still Trading at a Bargain

CGEM

Zacks

2 years ago

Fast-paced Momentum Stock Triumph Group (TGI) Is Still Trading at a Bargain

Diversified Healthcare Trust Provides Monthly SHOP Performance Update

CGEM

Business Wire

2 years ago

Diversified Healthcare Trust Provides Monthly SHOP Performance Update

CGEM

Zacks

2 years ago

The Zacks Analyst Blog Highlights Comcast, fuboTV, Hooker Furnishings, Lululemon Athletica and Skechers

Diversified Healthcare Trust Closes $941 Million Zero Coupon Senior Secured Notes with a Maturity Date in January 2026, and a One-Year Extension Option

CGEM

Business Wire

2 years ago

Diversified Healthcare Trust Closes $941 Million Zero Coupon Senior Secured Notes with a Maturity Date in January 2026, and a One-Year Extension Option

3 mREIT Stocks to Buy Despite Unsettling Mortgage Market

CGEM

Zacks

2 years ago

3 mREIT Stocks to Buy Despite Unsettling Mortgage Market

Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?

CGEM

Benzinga

2 years ago

Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

CGEM

ACCESSWIRE

2 years ago

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CGEM

GlobeNewswire

2 years ago

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

CGEM

GlobeNewswire

2 years ago

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 25%

CGEM

Simply Wall St.

2 years ago

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 25%

Chairman of the Board of Heartland Express Michael Gerdin Buys 4.7% More Shares

CGEM

Simply Wall St.

2 years ago

Latest Cullinan Oncology Inc. (CGEM) News on November 19, 2025

Share on Social Networks: